Savara Inc.
SVRA | NASDAQ
$5.44
-$0.01 (-0.18%)
Sep 22, 2026, 11:11 AM ET · Market open
Company Profile
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls | Chairman & Chief Executive Officer |
| Kate McCabe | Chief Legal Officer |
| Megan Carpenter | Chief People Officer |
| Anne Erickson | Chief Business & Corporate Affairs Officer |
| Brian Maurer | Head of Clinical Operations |
| Brian Robinson | Executive Vice President of Global Medical Affairs |
| Charles LaPree | Executive Vice President & Head of Global Regulatory Affairs |
| David L. Lowrance | Chief Financial & Administrative Officer and Secretary |
| Robert Lutz | COO & CFO |
| Siddharth J. Advant | Executive Vice President of Global Technical Operations |
| Yasmine Wasfi | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2026 | S-8 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Jul 24, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
| Jun 08, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Filing |
| Apr 24, 2026 | DEF 14A | Filing |
| Apr 10, 2026 | PRE 14A | Filing |
Savara Inc.
| Country | United States |
| IPO Date | Apr 27, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Matthew Pauls |
Contact Details
The Tannery Yardley,
Pennsylvania 19067 United States
Stock Details
| Ticker Symbol | SVRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001160308 |
| CUSIP Number | 805111101 |
| ISIN Number | US8051111016 |
| SIC Code | 2834 |
Recent News
- 29 days ago / businesswire.comSavara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
- 1 month ago / businesswire.comSavara Announces New Employment Inducement Grant
- 2 months ago / seekingalpha.comSavara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
- 2 months ago / zacks.comHere's Why You Should Add Savara Stock to Your Portfolio Now
- 4 months ago / businesswire.comSavara Announces Chief Financial and Administrative Officer Transition
- 4 months ago / businesswire.comSavara Announces Participation in the 2026 Jefferies Global Healthcare Conference
- 4 months ago / seekingalpha.comSavara: The Rare Disease Funnel Is Becoming A Commercial Asset
- 4 months ago / businesswire.comSavara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- 4 months ago / businesswire.comSavara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- 4 months ago / businesswire.comSavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Add to Watchlist
Select watchlists to add or remove SVRA